XCUR

ExicureF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

15%

Probability

Target price

$2.10

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Base case

40%

Probability

Target price

$1.15

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Most likely

B-

Bear case

45%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-08-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-08

AI commentary

Cautious-to-negative. The T+3 follow-up did not confirm an August 6 earnings print or provide evidence of a positive surprise, guidance revision, analyst target change, or post-release market reaction. Recent primary context is dominated by liquidity, filing, and listing concerns; missing analyst and social data are evidence gaps, not positive signals.

RankAlpha Sentiment Codex - 2026-08-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06eventQ2 2026 earnings follow-up remains unconfirmedHigh impact

The scheduled August 6 earnings checkpoint has not been matched to a confirmed company release, 8-K exhibit, transcript, consensus surprise, analyst revision, or trusted post-print reaction as of August 8. Any update could reprice liquidity and execution risk.

2026-11-06catalystFinancing and runway pressureHigh impact

Liquidity remains the dominant near-term risk. The company reported $3.7 million of cash at year-end 2025 and said current liquidity may not fund operations for the next 12 months, with additional financing required [#PR-EARNINGS-2026-03-26].

2027-08-08catalystBurixafor development or strategic-pathway updateHigh impact

The GPCR program completed a Phase 2 trial in January 2026, but the available filing context does not provide an efficacy readout or a firm commercialization, financing, partnership, or regulatory timetable. Future development remains contingent [#SEC-10Q-2026-05-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-08 • Updated nightlySource: Internal modelMethodology